{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.0","upperLimit":"12.0","value":"4.29"},{"groupId":"OG001","lowerLimit":"4.1","upperLimit":"8.1","value":"5.07"},{"groupId":"OG002","lowerLimit":"4.3","upperLimit":"8.3","value":"8.14"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"32"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"4"}],"units":"Participants"}],"description":"Time-to-response is calculated as the time from enrollment to the first date of documented response (partial response or better). Tumor response of partial response (PR) or better was assessed using the International Myeloma Working Group (IMWG) Uniform Response Criteria. Partial response required ≥ 50% reduction of serum M-Protein and reduction in 24-hour urinary M protein by ≥ 90% or to \\< 200 mg per 24 hours. For those participants where POM + DEX were added, time-to-response was calculated from the date POM and DEX were added to the first date of documented response (PR or better).","dispersionType":"Full Range","groups":[{"description":"Durvalumab 1500 mg + Daratumumab 16 mg/kg were administered intravenously within a 28-day cycle for a maximum of 60 cycles","id":"OG000","title":"Simon Stage 1: D2 Arm"},{"description":"Durvalumab 1500 mg IV + Daratumumab IV 16 mg/kg + Pomalidomide 4 mg/day Oral + Dexamethasone 40 mg Oral (20 mg for \\> 75 Years Old) were administered within a 28-day cycle for a maximum of 60 cycles","id":"OG001","title":"Simon Stage 1: D2 + Pomalidomide + Dexamethasone"},{"description":"Durvalumab 1500 mg IV + Daratumumab 16 mg/kg IV + Pomalidomide 4 mg/day Oral + Dexamethasone 40 mg Oral (20 mg for \\> 75 Years Old) administered within a 28-day cycle for a maximum of 22 cycles","id":"OG002","title":"PD3 Arm"}],"paramType":"MEDIAN","populationDescription":"All enrolled participants who received at least 1 dose of the study medication, and who have measurable disease at baseline and at least 1 postbaseline efficacy assessment in the D2, D2 + Pomalidomide + Dexamethasone, and PD3 arms.","reportingStatus":"POSTED","timeFrame":"From enrollment to earliest documented response (up to approximately 66 months)","title":"Time-To-Response (TTR)","type":"SECONDARY","unitOfMeasure":"Weeks"}